# Infectious Disease Outbreak Intelligence - Examples

## Example 1: Novel Coronavirus Outbreak

### User Query
"New coronavirus detected in bats with potential human spillover risk. What drugs might work if it spreads?"

### Expected Output

```markdown
# Outbreak Intelligence Report: Novel Betacoronavirus

**Generated**: 2026-02-04 | **Status**: URGENT - Preparedness Assessment

---

## Executive Summary

This novel betacoronavirus shares key features with SARS-CoV-2, enabling rapid knowledge transfer. **Top drug candidates** based on structural similarity and docking:

1. **Nirmatrelvir (Paxlovid component)** ★★★ - Main protease inhibitor
2. **Remdesivir** ★★★ - RdRp inhibitor
3. **Molnupiravir** ★★☆ - Mutagenic nucleoside analog

**Recommended immediate actions**:
1. Stockpile nirmatrelvir/ritonavir (highest docking scores)
2. Prepare remdesivir supply chain
3. Sequence additional isolates for resistance surveillance

---

## 1. Pathogen Profile

### 1.1 Taxonomic Classification

| Property | Value |
|----------|-------|
| **Organism** | Novel betacoronavirus (provisional) |
| **Type** | RNA virus (+ssRNA) |
| **Family** | Coronaviridae |
| **Genus** | Betacoronavirus |
| **Subgenus** | Sarbecovirus (based on phylogeny) |
| **Closest relative** | SARS-CoV-2 (87% genome identity) |

### 1.2 Related Pathogens with Drug Precedent

| Pathogen | Identity | Approved Drugs | Transferability |
|----------|----------|----------------|-----------------|
| SARS-CoV-2 | 87% | Nirmatrelvir, Remdesivir, Molnupiravir | HIGH |
| SARS-CoV | 79% | (Remdesivir EUA) | HIGH |
| MERS-CoV | 52% | None approved | MEDIUM |
| HCoV-OC43 | 45% | None specific | LOW |

**Assessment**: High drug transferability expected from SARS-CoV-2 therapeutics.

*Source: NCBI Taxonomy, BLAST alignment*

---

## 2. Druggable Targets

### 2.1 Prioritized Target List

| Rank | Target | Gene | Function | Score | Drug Precedent |
|------|--------|------|----------|-------|----------------|
| 1 | Main protease (Mpro) | NSP5 | Polyprotein cleavage | 95 | Nirmatrelvir |
| 2 | RdRp (NSP12) | NSP12 | RNA replication | 92 | Remdesivir |
| 3 | Papain-like protease | NSP3 | Deubiquitination | 78 | GRL0617 |
| 4 | Spike protein | S | Host entry | 75 | Antibodies |
| 5 | Helicase | NSP13 | RNA unwinding | 68 | None approved |

### 2.2 Top Target: Main Protease (Mpro)

| Property | Value |
|----------|-------|
| **Gene** | NSP5 (polyprotein position 3264-3569) |
| **Length** | 306 amino acids |
| **Function** | Cleaves viral polyprotein at 11 sites |
| **Essentiality** | Absolute - no viral replication without Mpro |
| **Conservation** | 96% identity with SARS-CoV-2 Mpro |
| **Active site** | Cys145-His41 catalytic dyad (100% conserved) |

**Critical finding**: Active site 100% conserved → nirmatrelvir expected to work.

*Source: UniProt, sequence alignment*

---

## 3. Target Structures

### 3.1 Structure Prediction Results

| Target | Method | Length | Mean pLDDT | Docking Ready |
|--------|--------|--------|------------|---------------|
| Mpro | AlphaFold2 | 306 aa | 94.2 | ✓ Excellent |
| RdRp | AlphaFold2 | 932 aa | 91.8 | ✓ Yes |
| PLpro | AlphaFold2 | 315 aa | 87.3 | ✓ Yes |

### 3.2 Mpro Structure Quality

| Region | Residues | pLDDT | Functional Role |
|--------|----------|-------|-----------------|
| Domain I | 8-101 | 95.1 | Substrate binding |
| Domain II | 102-184 | 94.8 | Catalytic |
| Domain III | 201-303 | 92.4 | Dimerization |
| **Active site** | C145, H41 | **97.2** | Catalysis |
| S1 pocket | F140, H163 | 96.8 | Substrate specificity |

**Docking Assessment**: Structure highly suitable; active site pLDDT 97.2.

*Source: NVIDIA NIM via `NvidiaNIM_alphafold2`*

---

## 4. Drug Repurposing Screen

### 4.1 Candidate Sources

| Source | Candidates | FDA Approved |
|--------|------------|--------------|
| SARS-CoV-2 drugs | 5 | 3 |
| Broad-spectrum antivirals | 12 | 8 |
| Protease inhibitors | 8 | 6 |
| RdRp inhibitors | 6 | 4 |
| **Total unique** | **24** | **15** |

### 4.2 Docking Results - Mpro Target

| Rank | Drug | Original Indication | Docking Score | Evidence |
|------|------|---------------------|---------------|----------|
| 1 | **Nirmatrelvir** | COVID-19 | 0.94 | ★★★ FDA approved |
| 2 | **Ensitrelvir** | COVID-19 (Japan) | 0.91 | ★★☆ Approved Japan |
| 3 | Boceprevir | HCV | 0.82 | ★☆☆ In vitro only |
| 4 | Lopinavir | HIV | 0.78 | ★☆☆ Mixed results |
| 5 | GRL0617 | Research | 0.75 | ☆☆☆ Preclinical |

### 4.3 Docking Results - RdRp Target

| Rank | Drug | Docking Score | Evidence |
|------|------|---------------|----------|
| 1 | **Remdesivir** | 0.93 | ★★★ FDA approved |
| 2 | **Molnupiravir** | 0.87 | ★★★ FDA approved |
| 3 | Favipiravir | 0.84 | ★★☆ Approved some countries |
| 4 | Sofosbuvir | 0.81 | ★☆☆ In vitro active |
| 5 | Ribavirin | 0.72 | ★☆☆ Weak activity |

### 4.4 Top Candidate: Nirmatrelvir

| Property | Value |
|----------|-------|
| **Docking score** | 0.94 (excellent, >reference) |
| **Mechanism** | Covalent inhibitor of Mpro active site |
| **FDA status** | Approved (with ritonavir as Paxlovid) |
| **Key binding** | C145 (covalent), H163 (H-bond) |
| **Expected efficacy** | HIGH (conserved target) |

*Source: NVIDIA NIM via `NvidiaNIM_diffdock`, ChEMBL*

---

## 5. Literature Intelligence

### 5.1 Relevant Knowledge Base

| Topic | Key Insight | Source |
|-------|-------------|--------|
| Mpro inhibitors | Conserved active site across sarbecoviruses | PMID:35892324 |
| Resistance | E166V mutation reduces nirmatrelvir binding | PMID:36112789 |
| RdRp inhibitors | Remdesivir active against all tested coronaviruses | PMID:34567890 |

### 5.2 Surveillance Considerations

**Monitor for resistance mutations**:
- Mpro: E166V, H172Y (nirmatrelvir resistance)
- RdRp: F480L, V557L (remdesivir resistance)

*Source: PubMed literature review*

---

## 6. Recommendations

### 6.1 Immediate Actions (Preparedness)

| Priority | Action | Rationale |
|----------|--------|-----------|
| 1 | **Stockpile Paxlovid** | Highest docking score, FDA approved |
| 2 | **Secure remdesivir supply** | Backup, especially for severe cases |
| 3 | **Sequence surveillance** | Monitor for resistance mutations |
| 4 | **Prepare clinical protocols** | Ready if human cases occur |

### 6.2 If Human Spillover Occurs

1. **First-line**: Paxlovid (nirmatrelvir/ritonavir) within 5 days of symptoms
2. **Hospitalized**: Add remdesivir
3. **Resistance detected**: Consider molnupiravir or combination therapy

### 6.3 Research Priorities

1. Confirm in vitro activity of top candidates against isolate
2. Animal model efficacy studies
3. Develop resistance monitoring panel
4. Evaluate antibody cross-reactivity from COVID-19 vaccines

---

## 7. Data Gaps

| Gap | Impact | Mitigation |
|-----|--------|------------|
| In vitro confirmation | Docking is predictive | Priority testing needed |
| Resistance baseline | Unknown starting point | Sequence all isolates |
| Human PK unknown | Dosing uncertain | Use COVID-19 dosing initially |

---

## 8. Data Sources

| Tool | Query | Purpose |
|------|-------|---------|
| NCBI_Taxonomy | coronavirus | Classification |
| UniProt_search | Novel coronavirus polyprotein | Target proteins |
| NvidiaNIM_alphafold2 | Mpro, RdRp sequences | Structure prediction |
| NvidiaNIM_diffdock | Top 24 drugs | Docking screen |
| ChEMBL_search_drugs | coronavirus antivirals | Drug candidates |
| PubMed_search_articles | coronavirus drug resistance | Literature |
```

---

## Example 2: Drug-Resistant Bacterial Infection

### User Query
"Hospital outbreak of carbapenem-resistant Klebsiella pneumoniae. What treatment options exist?"

### Expected Output (Key Sections)

```markdown
# Outbreak Intelligence Report: Carbapenem-Resistant Klebsiella pneumoniae (CRKP)

**Generated**: 2026-02-04 | **Status**: URGENT - Active Outbreak

---

## Executive Summary

CRKP infections have limited treatment options. **Top candidates**:

1. **Ceftazidime-avibactam** ★★★ - BL/BLI combination (if KPC-producing)
2. **Meropenem-vaborbactam** ★★★ - BL/BLI combination
3. **Cefiderocol** ★★☆ - Siderophore cephalosporin (last resort)

**CRITICAL**: Carbapenemase type must be determined to guide therapy.

| Carbapenemase | Recommended Treatment |
|---------------|----------------------|
| **KPC** | Ceftazidime-avibactam OR meropenem-vaborbactam |
| **MBL (NDM, VIM)** | Cefiderocol OR aztreonam-avibactam |
| **OXA-48** | Ceftazidime-avibactam |

---

## 2. Resistance Mechanism Analysis

### 2.1 Carbapenemase Types

| Enzyme | Class | Prevalence | Key Feature |
|--------|-------|------------|-------------|
| KPC | Class A | 60-70% | Inhibited by avibactam |
| NDM | Class B (MBL) | 15-20% | NOT inhibited by avibactam |
| OXA-48 | Class D | 10-15% | Variable inhibition |
| VIM | Class B (MBL) | 5-10% | Requires cefiderocol |

### 2.2 Critical Testing

**MUST obtain before treatment**:
1. Carbapenemase gene testing (PCR or phenotypic)
2. Antimicrobial susceptibility testing
3. MIC for candidate agents

---

## 4. Treatment Options

### 4.1 Ranked by Evidence (KPC-Producing CRKP)

| Rank | Drug | Mechanism | Evidence | Notes |
|------|------|-----------|----------|-------|
| 1 | **Ceftazidime-avibactam** | BL + BLI | ★★★ RCT data | First-line for KPC |
| 2 | **Meropenem-vaborbactam** | BL + BLI | ★★★ RCT data | Alternative |
| 3 | **Imipenem-relebactam** | BL + BLI | ★★☆ Limited data | If others fail |
| 4 | Tigecycline | Protein synthesis | ★☆☆ High mortality | Last resort |
| 5 | Colistin | Cell membrane | ★☆☆ Nephrotoxicity | Last resort |

### 4.2 For MBL-Producing CRKP (NDM, VIM)

| Drug | Activity | Evidence |
|------|----------|----------|
| **Cefiderocol** | Active | ★★☆ RCT, mortality concern |
| **Aztreonam-avibactam** | Active | ★★☆ Phase 3 |
| Ceftazidime-avibactam | NOT active | ❌ MBL hydrolyzes |

---

## 6. Recommendations

### 6.1 Immediate Actions

1. **Test carbapenemase type** - Critical for drug selection
2. **Start empiric therapy** - Ceftazidime-avibactam + aminoglycoside
3. **Infection control** - Contact precautions, cohorting
4. **ID consult** - All CRKP cases

### 6.2 Empiric Therapy (Pending Testing)

```
If KPC suspected (most common):
→ Ceftazidime-avibactam 2.5g IV q8h

If MBL suspected (NDM endemic area):
→ Cefiderocol 2g IV q8h OR Aztreonam + avibactam

If critically ill:
→ Combination therapy until susceptibilities available
```
```

---

## Example 3: Limited Information Scenario

### User Query  
"Novel virus isolated from agricultural workers with respiratory symptoms. Genome sequenced but not yet classified. What can we do?"

### Expected Output (Key Sections)

```markdown
# Outbreak Intelligence Report: Unclassified Respiratory Virus

**Status**: URGENT - Limited Data Available

---

## Executive Summary

With genome sequence available but taxonomic classification pending, we can still identify drug targets through sequence homology.

**Approach**:
1. BLAST genome against viral databases → Identify closest relatives
2. Predict key proteins → Prioritize by conservation
3. Dock broad-spectrum antivirals → Generate initial candidate list

**Initial candidates** (pending classification):
- Broad-spectrum polymerase inhibitors (favipiravir, ribavirin)
- Protease inhibitors (if protease identified)

---

## 1. Preliminary Classification

### 1.1 BLAST Results (Top Hits)

| Organism | Identity | E-value | Interpretation |
|----------|----------|---------|----------------|
| Influenza A H5N1 | 72% | 1e-89 | Possible orthomyxovirus |
| Influenza B | 65% | 1e-67 | Similar family |
| Thogoto virus | 58% | 1e-45 | Distant relative |

**Provisional Classification**: Likely orthomyxovirus (influenza-like)

### 1.2 Implications

If orthomyxovirus confirmed:
- **Neuraminidase inhibitors** (oseltamivir, zanamivir) may be active
- **Cap-dependent endonuclease inhibitors** (baloxavir) may be active
- **M2 inhibitors** likely inactive (resistance)

---

## 4. Preliminary Drug Screen

### 4.1 Broad-Spectrum Antivirals (No Classification Needed)

| Drug | Target | Activity Against | Priority |
|------|--------|------------------|----------|
| Favipiravir | RdRp | RNA viruses broadly | HIGH |
| Ribavirin | Multiple | RNA viruses broadly | MEDIUM |
| Remdesivir | RdRp | Coronaviruses mainly | LOW |

### 4.2 If Orthomyxovirus Confirmed

| Drug | Target | Activity | Priority |
|------|--------|----------|----------|
| **Oseltamivir** | Neuraminidase | Influenza A/B | HIGH |
| **Baloxavir** | Endonuclease | Influenza A/B | HIGH |
| Zanamivir | Neuraminidase | Influenza A/B | MEDIUM |

---

## 6. Recommendations

### With Limited Data

1. **Complete taxonomic classification** - Enables targeted drug selection
2. **Empiric broad-spectrum** - Favipiravir if RNA virus likely
3. **If influenza-like** - Prepare oseltamivir and baloxavir
4. **Supportive care** - Critical until specific therapy identified

### Research Priorities

1. Full genome annotation
2. In vitro antiviral testing
3. Animal model development
4. Serological assay development
```
